Natera stock: Natera targets 6 billion US dollars in 2029
Published on 11/17/2026 at 16:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNatera outlines its growth path
- Management said Signatera's average selling price could reach 1,450 US dollars by 2029, versus 1,290 US dollars today.
- Natera estimates a 20 billion to 40 billion US dollar market opportunity for personalized minimal residual disease testing.
- Coverage gains, reimbursement improvements and prospective outcomes data underpin the expansion plan.
Natera outlined a long-term expansion plan at the Wolfe Research Healthcare Conference on November 10, with management targeting 6 billion US dollars in revenue by 2029. Investing.com, citing Reuters and a conference transcript, reported that Chief Financial Officer Mike Brophy presented the target as a long-term waystation rather than a final destination.
Signatera remains the growth engine
Management said Signatera's average selling price could rise from 1,290 US dollars today to 1,450 US dollars by 2029. The company also estimated a 20 billion to 40 billion US dollar total addressable market for personalized minimal residual disease testing.
The market framework uses roughly 2 million annual cancer diagnoses in the United States, about 10 tests per patient over the cancer journey and a long-term average selling price of 2,000 US dollars. Management said broader reimbursement, additional Medicare coverage and prospective outcomes data could support wider adoption.
Coverage and competition shape outlook
Natera said it has submitted 11 tumor-specific dossiers to Medicare's MolDx program and that the liver-cancer indication has already received coverage. Around 10 further submissions remain in process, making reimbursement progress an important condition for the pricing and volume assumptions.
Management also discussed competition in minimal residual disease testing and colorectal cancer screening. Natera said its product development, clinical evidence and prospective studies are intended to defend its position as more providers enter the market.
Natera stock traded at 254.75 euros on Lang & Schwarz at 16:40 CET on Tuesday, November 17, 2026.
Natera company facts
- Company: Natera, Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Primary exchange: Nasdaq
- Lang & Schwarz price: 254.75 euros at 16:40 CET on November 17, 2026
For broader US market developments, see Current market reports.
